The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 14 of the 31 sources its claims cite were checked for support.
Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells
Open accessAbstract
BACKGROUND: ), a process that has been shown to impair their function. Here, we evaluated the characteristics and function of MSCs cultured under hypoxia and hypothesized that, when compared to normoxia, dedicated hypoxia will augment the functional characteristics of MSCs. METHODS: ) culture. In our second study, we evaluated the functional characteristics of MSC cultured under short-term 2% and 5% hypoxia. MSCs were evaluated for their metabolic activity, proliferation, viability, clonogenicity, gene expression, and secretory capacity. RESULTS: In long-term culture, common MSC surface marker expression (CD44 and CD105) dropped under hypoxia. Additionally, in long-term culture, MSCs proliferated significantly slower and provided lower yields under hypoxia. Conversely, in short-term culture, MSCs proliferated significantly faster under hypoxia. In both long-term and short-term cultures, MSC metabolic activity was significantly higher under hypoxia. Furthermore, MSCs cultured under hypoxia had upregulated expression of VEGF with concomitant downregulation of HMGB1 and the apoptotic genes BCL-2 and CASP3. Finally, in both hypoxia cultures, the pro-inflammatory cytokine, IL-8, was suppressed, while levels of the anti-inflammatories, IL-1ra and GM-CSF, were elevated in short-term hypoxia only. CONCLUSIONS: In this study, we demonstrate that hypoxia augments the therapeutic characteristics of both porcine and human MSCs. Yet, short-term 2% hypoxia offers the greatest benefit overall, exemplified by the increase in proliferation, self-renewing capacity, and modulation of key genes and the inflammatory milieu as compared to normoxia. These data are important for generating robust MSCs with augmented function for clinical applications.
Overview
CoChat Summary
## TL;DR
Short-term physiological hypoxia improved mesenchymal stem cell (MSC) function more than long-term hypoxia, with the strongest overall effects seen at 2% O2 for 48 h. Across human and porcine bone marrow MSCs, hypoxia increased proliferation and metabolic activity while shifting gene expression and secreted factors toward a more therapeutic profile.
## Key findings
- In the first experiment (1% O2), 48 h hypoxia outperformed 10-day hypoxia overall: short-term hypoxia increased proliferation, while long-term hypoxia reduced surface marker expression and cell yield.
- Under hypoxia, metabolic activity increased significantly in both species and both culture durations; the paper reports p < 0.0001 for long-term culture and p < 0.01 for short-term hMSCs.
- In short-term hypoxia, 2% O2 gave the best overall balance of effects: proliferation increased in both species (p < 0.01 at 24 h for both; p < 0.05 at 48 h for hMSCs), clonogenicity increased, and VEGF was upregulated.
- Hypoxia suppressed IL-8 in both long-term and short-term cultures; in short-term hypoxia, GM-CSF and IL-1ra were increased in pMSCs, while BCL-2 and CASP3 were downregulated in hMSCs.
## Methods
- Human and porcine bone marrow MSCs were isolated from mononuclear cells and cultured under normoxia (~21% O2) or hypoxia (1%, 2%, or 5% O2) using a dedicated hypoxia station.
- Two studies were performed: 1% O2 for 10 days vs 48 h, then 24 h and 48 h at 2% or 5% O2; all experiments used P2–P3 MSCs and were run in triplicate.
- Outcomes included flow cytometry, CFU-F clonogenicity, metabolic activity, DNA-based proliferation, qRT-PCR for selected genes, and multiplex secretion assays; statistical testing used t tests and two-way ANOVA with Tukey post hoc tests.
## Limitations
- The paper states that the findings “will be corroborated in vivo” in a preclinical ARDS model, so the work is limited to in vitro experiments and does not yet show in vivo therapeutic efficacy.
- The text makes evident that species differences complicate generalization: several outcomes differed between human and porcine MSCs, and the authors explicitly note inter-species variation in MSC characteristics and function.
- Not stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
8 Valid · 0 Not valid · 3 Not checked · 89 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the bone marrow, MSCs reside in low oxygen tension (hypoxia), which has been shown to range from 1.5 to 4.2% oxygen depending on the location in the marrow space [23].”
§ Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells > Background
What the sources say
- Partly supportedcites [23] Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, Zaher W, Mortensen LJ, Alt C, Turcotte R, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature. 2014;508(7495):269–73. sourceExperimental — accuracy not yet measured
The paper’s main text (indexed as Abstract; page unavailable) reports low, location-dependent oxygen levels in mouse bone marrow. Its 1.5–4.2% range is specifically for measurements inside blood vessels, however, not for oxygen tension at MSCs; measured extravascular values ranged from 0.6–2.8%. The paper identifies nestin-positive cells as a subset of marrow MSCs but does not establish the quoted range as the oxygen tension those cells experience. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Clinical applications involving systemic administration of MSCs require a large number of cells (1–10 × 106 cells/kg) to demonstrate a therapeutic efficacy [27–29].”
§ Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells > Background
What the sources say
- Partly supportedcites [27] Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A. 2002;99(13):8932–7. sourceExperimental — accuracy not yet measured
The Methods (MSC Infusions) report target doses of 1 × 10^6 and 5 × 10^6 cells/kg, and the Results (Clinical Responses) report increased growth velocity in five children with osteogenesis imperfecta. The paper does not establish that systemic MSC treatment generally requires 1–10 × 10^6 cells/kg for efficacy, or identify a minimum effective dose. (LLM, conf=0.85)
- Not checked yetcites [28] Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363(9419):1439–41. source
- Not checked yetcites [29] Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidder HH, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010;59(12):1662–9. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Upregulation of the VEGF gene was evident in all hypoxia cultures, which is consistent with other studies [53–56].”
§ Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells > Discussion
What the sources say
- Not checked yetcites [53] Chang EI, Loh SA, Ceradini DJ, Chang EI, Lin SE, Bastidas N, Aarabi S, Chan DA, Freedman ML, Giaccia AJ, et al. Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor 1alpha stabilization during ischemia. Circulation. 2007;116(24):2818–29. source
- Not checked yetcites [54] Xue C, Shen Y, Li X, Li B, Zhao S, Gu J, Chen Y, Ma B, Wei J, Han Q, et al. Exosomes derived from hypoxia-treated human adipose mesenchymal stem cells enhance angiogenesis through the PKA signaling pathway. Stem Cells Dev. 2018;27(7):456–65. source
- Not checked yetcites [55] Han KH, Kim AK, Kim MH, Kim DH, Go HN, Kang D, Chang JW, Choi SW, Kang KS, Kim DI. Protein profiling and angiogenic effect of hypoxia-cultured human umbilical cord blood-derived mesenchymal stem cells in hindlimb ischemia. Tissue Cell. 2017;49(6):680–90. source
- Supportedcites [56] Liu J, Hao H, Xia L, Ti D, Huang H, Dong L, Tong C, Hou Q, Zhao Y, Liu H, et al. Hypoxia pretreatment of bone marrow mesenchymal stem cells facilitates angiogenesis by improving the function of endothelial cells in diabetic rats with lower ischemia. PLoS One. 2015;10(5):e0126715. source
The Results section, “The characterization of rat BM-MSCs cultured under hypoxic conditions,” reports increased VEGF-1α gene expression in BM-MSCs at each tested hypoxic oxygen concentration (2%, 5%, and 7%). This supports the claim as a comparison across the hypoxia cultures tested in the source paper. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Therefore, its downregulation in hypoxia may signify cytoprotection from cellular damage, such as production of reactive oxygen species, as seen in normoxia cultures [61, 62].”
§ Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells > Discussion
What the sources say
- Not checked yetcites [61] Luan ZG, Zhang XJ, Yin XH, Ma XC, Zhang H, Zhang C, Guo RX. Downregulation of HMGB1 protects against the development of acute lung injury after severe acute pancreatitis. Immunobiology. 2013;218(10):1261–70. source
- Partly supportedcites [62] Zhang X, Luan Z, Liang Y, Liu Y, Ma X. Downregulation of high mobility group box 1 attenuates the severity of acute lung injury in endotoxemic mice. Mol Med Rep. 2015;11(6):4513–7. sourceExperimental — accuracy not yet measured
The Results sections report that HMGB1 downregulation reduced lung injury and malondialdehyde levels in LPS-treated mice. They do not examine hypoxia or normoxia cultures, or directly report reactive oxygen species production, so the claim's specific setting and mechanism are not supported by this paper. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additionally, under 2% hypoxia, there was a significant increase in secretion of IFN-γ (in pMSCs, p < 0.05 at 24 h; in hMSCs, p < 0.01 at 24 and 48 h) while the opposite effect was seen under 5% hypoxia (in pMSCs, p < 0.05 at 24 h).”
§ Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells > Results > Hypoxia tension
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
65 more claims
Create a free account to see all 100 claims and to verify the 17 references still open.
- It may state two separate claims as one. 23
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the secretome obtained from hypoxia preconditioned-BM-MSCs upregulated the levels of FGF-2, IGF-1, TGF-β, IL-1β, IL-6 [123] and IL-8 [122] and enhanced multiple key processes to promote wound healing, including keratinocyte, fibroblast and endothelial cells proliferation and migration, as well as angiogenesis (Fig. 2) [38], [120], [123].”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [122]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have already demonstrated that hypoxia-preconditioned MSCs can frequently potentiate the therapeutic potential [122] of different types of MSCs, including BM-, UC- and AT-MSCs.”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [122]
Experimental — accuracy not yet measured
Citations
Cites
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600
Horwitz, E. M., Gordon, P. L., Koo, W. K. K., Marx, J. C., Neel, M. D., McNall, R. Y., Muul, L., & Hofmann, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132252399 · Cited by 1,650
Direct measurement of local oxygen concentration in the bone marrow of live animals
Spencer, J. A., Ferraro, F., Roussakis, E., Klein, A., Wu, J., Runnels, J. M., Zaher, W., Mortensen, L. J., Alt, C., Turcotte, R., et al. (2014) · Nature · doi:10.1038/nature13034 · Cited by 1,167
Gupta, N., Su, X., Popov, B., Lee, J. W., Serikov, V., & Matthay, M. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1855 · Cited by 931
Krasnodembskaya, A., Song, Y., Fang, X., Gupta, N., Serikov, V., Lee, J.-W., & Matthay, M. A. (2010) · Stem Cells · doi:10.1002/stem.544 · Cited by 849
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial
Wilson, J. G., Liu, K. D., Zhuo, H., Caballero, L., McMillan, M., Fang, X., Cosgrove, K., Vojnik, R., Calfee, C. S., Lee, J.-W., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70291-7 · Cited by 759
Lee, J. W., Fang, X., Gupta, N., Serikov, V., & Matthay, M. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907996106 · Cited by 715
Duijvestein, M., Vos, A. C. W., Roelofs, H., Wildenberg, M. E., Wendrich, B. B., Verspaget, H. W., Kooy-Winkelaar, E. M. C., Koning, F., Zwaginga, J. J., Fidder, H. H., et al. (2010) · Gut · doi:10.1136/gut.2010.215152 · Cited by 622
Mei, S. H. J., McCarter, S. D., Deng, Y., Parker, C. H., Liles, W. C., & Stewart, D. J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040269 · Cited by 619
Cited by
Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?
Trigo, C. M., Rodrigues, J. S., Camões, S. P., Solá, S., & Miranda, J. P. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.004 · Cited by 252
“…that the secretome obtained from hypoxia preconditioned-BM-MSCs upregulated the levels of FGF-2, IGF-1, TGF-b , IL-1 b , IL-6 [123] and IL-8 [122] and enhanced multiple key processes to promote wound healing, including keratinocyte, fibroblast and endothelial cells proliferation and…”
Emergence of the Stem Cell Secretome in Regenerative Engineering
Daneshmandi, L., Shah, S., Jafari, T., Bhattacharjee, M., Momah, D., Saveh-Shemshaki, N., Lo, K. W.-H., & Laurencin, C. T. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2020.04.013 · Cited by 224
Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice
Li, C., Zhao, H., Cheng, L., & Wang, B. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00698-y · Cited by 186
“When MSCs are cultured under long-term (10 days) hypoxia, such cells downregulate their surface markers including CD44 and CD105 [43].”
BackgroundChen, W., Wu, P., Yu, F., Luo, G., Qing, L., & Tang, J. (2022) · Cells · doi:10.3390/cells11223552 · Cited by 181
Engineering the MSC Secretome: A Hydrogel Focused Approach
Wechsler, M. E., Rao, V. V., Borelli, A. N., & Anseth, K. S. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001948 · Cited by 161
Metadata
- Authors
- Antebi, B., Rodriguez, L. A., Walker, K. P., Asher, A. M., Kamucheka, R. M., Alvarado, L., Mohammadipoor, A., & Cancio, L. C.
- Affiliations
- United States Army Institute of Surgical Research (US)
- Corresponding author
- Antebi, Ben
- ORCID
- Venue
- Stem Cell Research & Therapy
- Published
- 2018-10-11
- Volume
- 9
- Issue
- 1
- Pages
- 265-265
- ISSN
- 1757-6512 (ISSN-L)
- PMC
- PMC6180371
- OpenAlex
- W2897996477
- Cited by
- 137
- References
- 75
- Citations by year
- 2026: 13 · 2025: 10 · 2024: 18 · 2023: 28 · 2022: 23 · 2021: 21 · 2020: 14 · 2019: 10
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Stem Cell Research & Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- USAMRMC Combat Casualty Care RAD (X_018_2018)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Dentistry › Periodontics › Periodontal Regeneration and Treatments
- Keywords
- mesenchymal stem cells, hypoxia, short-term hypoxia, self-renewal, vascular endothelial growth factor, HMGB1, apoptosis, inflammatory cytokines, interleukin-8, interleukin-1 receptor antagonist, GM-CSF, therapeutic function
- MeSH terms
- Animals, Cell Differentiation, Cell Survival, Gene Expression Regulation, Humans, Oxygen, Swine, Time Factors, Signal Transduction, Cell Hypoxia, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-8, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Vascular Endothelial Growth Factor A, Cell Proliferation, Caspase 3, Interleukin 1 Receptor Antagonist Protein, Mesenchymal Stem Cells, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells. https://app.cochat.ai/papers/10.1186/s13287-018-1007-x
- The paper
- Antebi, B., Rodriguez, L. A., Walker, K. P., Asher, A. M., Kamucheka, R. M., Alvarado, L., Mohammadipoor, A., & Cancio, L. C. (2018). Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-018-1007-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.